DNA Chip Research Inc
TSE:2397
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (15.6), the stock would be worth ¥54 370.83 (95% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 287.1 | ¥1 000 000 |
0%
|
| Industry Average | 15.6 | ¥54 370.83 |
-95%
|
| Country Average | 22.4 | ¥77 875.88 |
-92%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
D
|
DNA Chip Research Inc
TSE:2397
|
7.4B JPY | 287.1 | -126.8 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 2 167.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.4B USD | 12.2 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
124B USD | 19.4 | 33.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 190.3 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 21.5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | -40.7 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.4B USD | 36.5 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.1B USD | 106.9 | 46.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.8B USD | 9.8 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.8B USD | 31.7 | 29.7 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 14.9 |
| Median | 22.4 |
| 70th Percentile | 35 |
| Max | 736 044 589.7 |
Other Multiples
DNA Chip Research Inc
Glance View
DNA Chip Research, Inc. engages in the business of contract analysis and Deoxyribonucleic Acid (DNA) chip technology development services. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 29 full-time employees. The company went IPO on 2004-03-18. The Contract Research segment is engaged in the microarray, next-generation sequencing experiment analysis to universities and research institutes, pharmaceutical and food companies. The Diagnostic segemnt utilizes genetic analysis technology to disseminate tests corresponding to social needs on personalized medicine and undiseased society. The main menu of the diagnostic business is EGFR-NGS Check. The Research and Development segment includes research on cancer diagnosis technology using next generation sequencer, as well as the development of RNA check.
